CancerApr 14, 2026
About 15% of men with a PSA level under 4.0 ng/mL, the traditional "normal" cutoff, have prostate cancer on biopsy. That single finding upended decades of assumptions about what a prostate specific antigen test can and can't tell you.
PSA is one of the most debated blood tests in medicine. Two enormous randomized trials gave seemingly opposite answers about whether screening saves lives. Guidelines have swung from recommending routine testing to advising against it, and back to something in between.
The confusion is understandable. But the research, once you piece it together, tells a more coherent story than the headlines suggest.
CancerApr 14, 2026
A single blood draw that detected cancer signals across more than 50 tumor types with a false positive rate under 1% sounds like it shouldn't exist yet, but a clinical validation study of over 4,000 participants showed exactly that. The Galleri test, developed by GRAIL, uses DNA methylation patterns in cell-free DNA to find cancer signals that standard screening was never designed to catch.
It's not a replacement for mammograms or colonoscopies. It's aimed at the cancers that have no screening test at all, the ones that tend to show up late and kill quickly.
So what does the science actually support, and where does the test fall short?
MammogramApr 14, 2026
Somewhere between 60% and 90% of women report at least some pain or discomfort during breast compression, depending on the study. That number is high, and it deserves an honest answer rather than dismissal. But the intensity and duration matter just as much as the frequency: most women rate the pain as mild to moderate, it resolves within minutes of the plates releasing, and only about 6 to 8% of women in large screening groups report severe pain, defined as a 7 or higher on a 0-to-10 scale.
So the truthful answer is: it will probably hurt some, it probably won't hurt a lot, and it will be over fast.
Cancer ScreeningApr 14, 2026
While colon cancer risk is often seen as age-related, newer research highlights how lifestyle, genetics, and even your body weight can drastically alter your odds. The good news? Many of these risk factors are modifiable.
Cancer ScreeningApr 14, 2026
The short answer is that a Pap smear can be uncomfortable, and for some women it can cause mild pain. However, the experience is usually brief and manageable and there are effective strategies proven to make the experience less painful. The level of discomfort varies greatly from person to person, depending on factors such as anatomy, age, anxiety, cultural expectations, and the way the procedure is performed.
Women's HealthApr 14, 2026
The Pap smear has been one of the greatest successes in preventive medicine. Since its introduction in the mid-20th century, countries with organized screening programs have seen cervical cancer mortality drop by as much as 70%.
The test is simple and inexpensive, yet enormously powerful when performed correctly. Despite this success, women often face confusion about when it can or should be scheduled. Menstrual bleeding raises a practical concern, not because it harms the patient, but because it may interfere with the test itself. Understanding the science behind how Pap smears work helps explain why timing matters.
Breast CancerApr 14, 2026
Mammography picks up 80 to 90 percent of breast cancers in women without symptoms, and when it catches cancer at stage I, clinical cure rates exceed 90 percent. That's a striking number. But here's the part that surprises most people: once stage I breast cancer is found and treated, piling on extra imaging scans to hunt for spread doesn't improve survival or quality of life. The evidence points to a simple, almost counterintuitive approach after treatment. One yearly mammogram. That's it.
Cancer ScreeningApr 14, 2026
Full-body MRI, sometimes marketed as a "preventive" or "executive" health scan, has become one of the hottest trends in proactive health care. The pitch is simple and appealing. But what does the research actually say about whether it is worth it for you?
For the average healthy adult, current evidence does not support routine full-body MRI screening. The scan finds confirmed cancers in only about 1 to 2% of people without symptoms, while triggering uncertain or false-positive findings in roughly a third of everyone scanned. For people with specific high-risk genetic conditions, the picture is very different, and the scan can be genuinely lifesaving.
Prostate CancerApr 14, 2026
Prostate cancer is the most common cancer in men and the second leading cause of cancer death worldwide. Nearly one in six men will face a diagnosis during their lifetime, and in the United States alone, hundreds of thousands of men are diagnosed each year. The disease often develops silently, with no symptoms until it has advanced, which makes screening especially important.
As Prostate Cancer Awareness Month nears its end, it's important to highlight the tests that make the greatest impact on early detection. While most doctors still rely on total PSA, clinical research shows that free PSA delivers stronger predictive value by distinguishing cancer from benign conditions and reducing unnecessary biopsies.
GeneticsApr 14, 2026
DNA methylation tests can pick up cancer signals earlier than imaging, work from something as simple as blood or urine, and even identify which organ is in trouble. That is genuinely impressive, and it is the validated, clinical side of this technology. But if you have been seeing ads for broad "epigenetic health" or "biological age" panels, those are a very different product, and the evidence behind them is far less solid.
The gap between what methylation testing can do in a specialist's hands and what is being marketed to the general public is wide. Understanding where the science actually stands helps you figure out whether any of this is worth your attention or your money right now.
Colon CancerApr 14, 2026
How well you prep doesn't just affect your comfort level. It directly determines whether the procedure actually works. The research is remarkably clear on this: inadequate colonoscopy prep is the single most common reason colonoscopies fail to find polyps and early cancers. In one nationwide screening study of more than 335,000 colonoscopies, even "fair" prep was linked to more than a 2.5-fold higher risk of dying from colorectal cancer compared to excellent prep.
The good news? The steps that matter most are straightforward, and the science gives you a clear playbook. This article covers what to do, when to do it, and why each step matters, all based on clinical guidelines, meta-analyses, and large observational studies.
Cancer ScreeningApr 14, 2026
For decades, mammography has been considered the gold standard for breast cancer screening, particularly in women over the age of 40. Yet, as technology advances and as researchers examine the limitations of mammography, ultrasound has emerged as a critical complementary tool and, in certain contexts, a potential alternative. Understanding what each modality truly reveals about early cancer detection carries profound consequences for both risk assessment and personal decision-making.
Cancer ScreeningApr 14, 2026
Cologuard detects about 92% of colorectal cancers from a stool sample you collect at home. That's genuinely impressive. But here's the critical distinction most people miss: catching cancer is not the same as preventing it. Colonoscopy can find precancerous polyps and remove them during the same procedure, stopping cancer before it starts. Cologuard can flag some of those polyps but can't do anything about them, and it misses a substantial number of the advanced ones colonoscopy would catch.
Both tests are guideline-endorsed options for average-risk adults. The choice between them isn't about one being "good" and the other "bad." It's about understanding what each test actually does, what it misses, and what happens after you get a result.
Cancer ScreeningApr 14, 2026
The Galleri test screens for signals from over 50 types of cancer using a single blood draw. It works by analyzing cell-free DNA methylation patterns, and the clinical data behind it is both genuinely promising and genuinely limited. The CCGA validation study showed 99.5% specificity and the ability to predict where a cancer signal originates with 88.7% accuracy. But sensitivity for Stage I cancers was just 16.8%, meaning the test misses most cancers at their earliest, most treatable point. If you're considering spending $849 on this test, you deserve a clear picture of what the science actually shows.
Cancer ScreeningApr 14, 2026
Prenuvo specializes in whole-body magnetic resonance imaging (MRI) designed not for patients with symptoms but for people seeking early detection of disease. Unlike traditional MRIs that focus on a single body part after symptoms arise, Prenuvo scans from head to pelvis, capturing images of multiple organ systems in a single session. The company markets itself as a tool for early detection of cancers, aneurysms, and other silent but potentially life-threatening conditions. Costing $2,000 or more per scan, let’s dig into whether Prenuvo is worth its price tag.
Breast MRIApr 14, 2026
Breast MRI is one of the most sensitive tools for detecting cancer in dense or high-risk breasts, but it can feel intimidating if you’ve never had one. This post breaks down exactly what happens during the scan, how to prepare, and tips to make it easier.
Urinary HealthApr 14, 2026
Up to 20% of the general population will, at some point, test positive for occult blood in urine. That is a staggering number for a result that can send you spiraling. The reality: most of these findings are benign. But about 2–5% of adults with confirmed, asymptomatic microscopic hematuria do have a urinary tract malignancy, and others have early kidney disease they don't know about. The challenge isn't the test result itself. It's knowing who needs to act on it and who doesn't.
Occult blood in urine simply means red blood cells are present in amounts too small to see, typically caught on a routine dipstick test. It is not a diagnosis. It is a signal, and signals require context.
Cancer ScreeningApr 14, 2026
You may have heard that a breast MRI is the “best” test for finding breast cancer. And in many ways, it is. MRI can detect cancers that mammograms and ultrasounds miss, especially in women with dense breasts or high genetic risk. But here’s the part that often gets left out: breast MRI is not for routine screening in average-risk women. It’s a specialized tool that’s extremely powerful in the right context, but not always helpful if used too broadly. Let’s break down what a breast MRI is, who needs it, and what to consider before getting one.
Body CompositionApr 14, 2026
Dual-energy X-ray absorptiometry, more commonly known as a DEXA scan, is a specialized imaging technique widely used to assess bone mineral density (BMD). It is a non-invasive, low-radiation tool typically employed in diagnosing osteoporosis and evaluating fracture risk. Given its routine use, especially in aging populations and cancer patients undergoing certain therapies, a common question arises: can a DEXA scan detect cancer?
While DEXA scans are not designed to directly identify or diagnose cancer, emerging evidence suggests that under certain circumstances, they may incidentally reveal signs consistent with metastatic disease. This article aims to explain what a DEXA scan is capable of, how it might relate to cancer detection, and what the research says about its diagnostic limitations and possibilities.
Cancer ScreeningApr 14, 2026
Early detection of cancer significantly improves survival rates. The Galleri test requires only a simple blood draw and scans for over 50 types of cancer. Known for its high specificity, the test does, however, have limitations in sensitivity, particularly in the early stages of cancer. Nevertheless, it offers invaluable information into potential cancer threats, especially for those genetically predisposed to the disease.
